Company Overview: Harvard Apparatus Regenerative Technology

Industry News

29 Jun

Biostage Files for FDA Orphan Drug Designation for Cellspan™ Esophageal Implant

Orphan Drug Designation Provides Range of Benefits Including Seven-Year Market Exclusivity HOLLISTON, Mass., June 29, 2016 /PRNewswire/ — Biostage, Inc. (BSTG), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, today announced it has submitted an application with the...

Read more

21 Jun

Biostage CEO Provides Mid-Year Update to Shareholders

Overview Notes Continued Progress with Organ Regeneration Program HOLLISTON, Mass., June 21, 2016 /PRNewswire/ — Biostage, Inc. (BSTG), a biotechnology company developing bioengineered organ implants to treat cancer and other life-threatening conditions of the esophagus, bronchus and trachea, today updated its shareholders on the Company’s progress and outlook in the...

Read more

19 May

Bioengineered Organ Implant Developer Biostage to Present at Marcum and LD Micro Investor Conferences on June 2nd in NYC and June 7th in LA

HOLLISTON, Mass., May 19, 2016 /PRNewswire/ — Biostage, Inc. (BSTG), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, today announced that CEO Jim McGorry and CFO Tom McNaughton will present at the Marcum and LD Micro investor conferences...

Read more

16 May

Biostage Announces $5 Million At-The-Market Offering

HOLLISTON, Mass., May 16, 2016 /PRNewswire/ — Biostage, Inc. (BSTG) (“Biostage” or “the Company”), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, today announced that it has entered into definitive agreements with institutional investors for an offering of shares...

Read more

12 May

Biostage Successfully Regenerates Esophagus in Groundbreaking Pre-Clinical Work with Mayo Clinic; Data Provides ‘Proof of Concept’ to Seek FDA Approval for Clinical Trials

Biostage Hosts Conference Call Today at 9:00 a.m. ET to Review Research Findings and Their Significance for Advancing Regulatory and Clinical Goals. HOLLISTON, Mass., May 12, 2016 /PRNewswire/ — Biostage, Inc. (BSTG), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus...

Read more

3 May

Bioengineered Organ Implant Developer Biostage to Host Pre-Clinical Research Update and Q1 Call Thursday, May 12th at 9:00 am ET

HOLLISTON, Mass., May 3, 2016 /PRNewswire/ — Biostage, Inc. (BSTG) a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, will host a conference call to provide an update on their collaborative large animal pre-clinical research and to review its first quarter results on...

Read more

22 Apr

Biostage Appoints Ginger Abraham-Freel as Director of Quality and Operations to Advance its Bioengineered Organ Implants

HOLLISTON, Mass., April 22, 2016 /PRNewswire/ — Biostage, Inc. (BSTG), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today announced that Ginger A. Abraham-Freel has joined the company as Director of Quality and Operations, a new position at Biostage. Having a dedicated...

Read more

31 Mar

Harvard Apparatus Regenerative Technology Changes Name to Biostage, Inc. (NASDAQ: BSTG)

Name Change is Capstone of Corporate Rebranding Initiative for the Bioengineered Organ Implant Developer (www.biostage.com) – Trading Under Nasdaq Symbol “BSTG” begins April 1, 2016 – HOLLISTON, Mass., March 31, 2016 /PRNewswire/ — Harvard Apparatus Regenerative Technology, Inc. (HART) announced today it has changed its corporate name to Biostage, Inc....

Read more

18 Mar

Bioengineered Organ Implant Developer HART Reviews Progress and Q4 2015 Results

Hosts Management Update Call Today at 5:00pm EDT HOLLISTON, Mass., March 17, 2016 /PRNewswire/ — Harvard Apparatus Regenerative Technology, Inc. (HART), announced its financial results for the fourth quarter and year ended December 31, 2015 and reviewed its corporate and research progress and plans. HART is a biotechnology company developing...

Read more

Page 1 of 41234

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address